RCT | Atogepant outperforms placebo in reducing migraines over 12 weeks
2 Aug, 2023 | 13:56h | UTCAtogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)